Alnylam Pharmaceuticals, Inc. – LSE:0HD2.L
Alnylam Pharmaceuticals stock price today
Alnylam Pharmaceuticals stock price monthly change
Alnylam Pharmaceuticals stock price quarterly change
Alnylam Pharmaceuticals stock price yearly change
Alnylam Pharmaceuticals key metrics
Market Cap | 31.87B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -2.65 |
Revenue | 2.00B |
EBITDA | -122.29M |
Income | -332.07M |
Revenue Q/Q | 54.82% |
Revenue Y/Y | 75.20% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -6.1% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlnylam Pharmaceuticals stock price history
Alnylam Pharmaceuticals stock forecast
Alnylam Pharmaceuticals financial statements
| Jun 2023 | 318.75M | -276.02M | -86.59% |
|---|---|---|---|
| Sep 2023 | 750.53M | 147.75M | 19.69% |
| Dec 2023 | 439.71M | -137.87M | -31.35% |
| Mar 2024 | 494.33M | -65.93M | -13.34% |
| Sep 2025 | 583.24M | -23.22M | -3.98% |
|---|---|---|---|
| Oct 2025 | 611.62M | -74.74M | -12.22% |
| Dec 2025 | 728.62M | 12.33M | 1.69% |
| Mar 2026 | 654.03M | 16.70M | 2.55% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3402396000 | 3.81B | 112% |
|---|---|---|---|
| Sep 2023 | 3839073000 | 4.00B | 104.32% |
| Dec 2023 | 3829880000 | 4.05B | 105.76% |
| Mar 2024 | 3824386000 | 4.04B | 105.73% |
| Jun 2023 | -58.98M | -8.71M | 53.39M |
|---|---|---|---|
| Sep 2023 | 359.41M | -10.76M | 33.13M |
| Dec 2023 | -29.79M | -240.65M | 39.22M |
| Mar 2024 | -81.51M | -67.62M | 28.91M |
Alnylam Pharmaceuticals alternative data
| Aug 2023 | 2,002 |
|---|---|
| Sep 2023 | 2,002 |
| Oct 2023 | 2,002 |
| Nov 2023 | 2,002 |
| Dec 2023 | 2,002 |
| Jan 2024 | 2,002 |
| Feb 2024 | 2,002 |
| Mar 2024 | 2,100 |
| Apr 2024 | 2,100 |
| May 2024 | 2,100 |
| Jun 2024 | 2,100 |
| Jul 2024 | 2,100 |
Alnylam Pharmaceuticals other data
| Patent |
|---|
Grant Utility: Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression Filling date: 4 Nov 2019 Issue date: 20 Sep 2022 |
Grant Utility: Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof Filling date: 27 Jul 2020 Issue date: 6 Sep 2022 |
Grant Utility: Modified double-stranded RNA agents Filling date: 10 Nov 2021 Issue date: 30 Aug 2022 |
Grant Filling date: 15 Sep 2020 Issue date: 23 Aug 2022 |
Application Filling date: 14 Feb 2022 Issue date: 11 Aug 2022 |
Grant Filling date: 15 Jun 2021 Issue date: 9 Aug 2022 |
Application Filling date: 31 Jan 2022 Issue date: 21 Jul 2022 |
Application Filling date: 18 Aug 2021 Issue date: 7 Jul 2022 |
Application Filling date: 13 Aug 2021 Issue date: 7 Jul 2022 |
Application Filling date: 15 May 2020 Issue date: 7 Jul 2022 |
| Insider | Compensation |
|---|---|
Dr. John M. Maraganore (1963) Chief Executive Officer & Executive Director | $1,790,000 |
Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA (1963) Pres & Chief Operating Officer | $1,140,000 |
Dr. Akshay K. Vaishnaw (1963) Pres of R&D | $986,100 |
| Mr. Jeffrey V. Poulton (1968) Chief Financial Officer | $681,750 |
Ms. Christine Regan Lindenboom Senior Vice President of Investor Relations & Corporation Communications | |
Ms. Laurie Bartlett Keating J.D. Executive Vice President, Chief Legal Officer & Sec. | |
Ms. Nereyda Garcia Global Head of Ethics & Compliance | |
Dr. Alfred W. Boyle Ph.D. Senior Vice President of Technical Operations | |
Dr. Kevin Fitzgerald Senior Vice President & Chief Scientific Officer | |
Mr. Mark Baglin Vice President of Global Marketing |
-
What's the price of Alnylam Pharmaceuticals stock today?
One share of Alnylam Pharmaceuticals stock can currently be purchased for approximately $100.8.
-
When is Alnylam Pharmaceuticals's next earnings date?
Unfortunately, Alnylam Pharmaceuticals's (0HD2.L) next earnings date is currently unknown.
-
Does Alnylam Pharmaceuticals pay dividends?
No, Alnylam Pharmaceuticals does not pay dividends.
-
How much money does Alnylam Pharmaceuticals make?
Alnylam Pharmaceuticals has a market capitalization of 31.87B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 76.23% to 1.83B US dollars.
-
What is Alnylam Pharmaceuticals's stock symbol?
Alnylam Pharmaceuticals, Inc. is traded on the LSE under the ticker symbol "0HD2.L".
-
What is Alnylam Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Alnylam Pharmaceuticals?
Shares of Alnylam Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Alnylam Pharmaceuticals's key executives?
Alnylam Pharmaceuticals's management team includes the following people:
- Dr. John M. Maraganore Chief Executive Officer & Executive Director(age: 62, pay: $1,790,000)
- Dr. Yvonne L. Greenstreet M.B.A., MBChB, MBA Pres & Chief Operating Officer(age: 62, pay: $1,140,000)
- Dr. Akshay K. Vaishnaw Pres of R&D(age: 62, pay: $986,100)
- Mr. Jeffrey V. Poulton Chief Financial Officer(age: 57, pay: $681,750)
- Ms. Christine Regan Lindenboom Senior Vice President of Investor Relations & Corporation Communications
- Ms. Laurie Bartlett Keating J.D. Executive Vice President, Chief Legal Officer & Sec.
- Ms. Nereyda Garcia Global Head of Ethics & Compliance
- Dr. Alfred W. Boyle Ph.D. Senior Vice President of Technical Operations
- Dr. Kevin Fitzgerald Senior Vice President & Chief Scientific Officer
- Mr. Mark Baglin Vice President of Global Marketing
-
How many employees does Alnylam Pharmaceuticals have?
As Jul 2024, Alnylam Pharmaceuticals employs 2,100 workers.
-
When Alnylam Pharmaceuticals went public?
Alnylam Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 29 Jan 2018.
-
What is Alnylam Pharmaceuticals's official website?
The official website for Alnylam Pharmaceuticals is alnylam.com.
-
Where are Alnylam Pharmaceuticals's headquarters?
Alnylam Pharmaceuticals is headquartered at 675 West Kendall Street, Cambridge, MA.
-
How can i contact Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's mailing address is 675 West Kendall Street, Cambridge, MA and company can be reached via phone at +61 75518200.
Alnylam Pharmaceuticals company profile:
Alnylam Pharmaceuticals, Inc.
alnylam.comLSE
2,100
Medical - Pharmaceuticals
Healthcare
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Cambridge, MA 02142
:
ISIN: US02043Q1076
:
